1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Boston Scientific to Acquire Valencia Technologies, Expanding into Implantable Tibial Nerve Stimulation

14 Jan 2026
Admin
News Article

Boston Scientific to Acquire Valencia Technologies, Expanding into Implantable Tibial Nerve Stimulation

Boston Scientific Corporation has announced a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical device company focused on bladder dysfunction therapies.

The deal strengthens Boston Scientific’s Urology portfolio and marks its entry into implantable tibial nerve stimulation (ITNS).

Why This Acquisition Matters?

Overactive bladder (OAB) is common. Treatment rates are not.

Nearly 30 million US adults aged 40+ experience bothersome OAB symptoms
OAB affects quality of life, sleep, mental health, and productivity
Only ~19% of patients receive treatment beyond lifestyle and behavioural changes

This gap creates a clear opportunity for minimally invasive, long-term solutions.

The eCoin System: A New Approach to UUI

Valencia’s flagship product, the eCoin System, is an implantable tibial nerve stimulation device designed to treat urge urinary incontinence (UUI).

Key features:

FDA approved in 2022
Coin-sized implant, placed near the ankle
Implanted via a minimally invasive procedure
Delivers automatic, intermittent tibial nerve stimulation
Regulates bladder–brain signalling without daily patient intervention

Clinical Performance Snapshot

In the pivotal clinical trial:

68% of patients achieved at least a 50% reduction in UUI episodes

The device is intended for:

Patients who responded to percutaneous tibial nerve stimulation (PTNS)
Patients intolerant to, or inadequately treated by, conservative therapies

Strategic Fit for Boston Scientific

This acquisition expands Boston Scientific into a high-growth adjacency within pelvic health.

Meghan Scanlon, SVP and President of Urology at Boston Scientific, said the eCoin system complements the company’s existing offerings and enables a more complete care continuum for bladder dysfunction.

In short:

ITNS fits naturally alongside existing urology solutions
The portfolio moves beyond episodic treatment toward long-term neuromodulation

Deal Timeline and Financial Impact

Expected close: First half of 2026
Conditions: Customary regulatory and closing requirements
Financial impact:
- Immaterial on adjusted EPS in 2026
- More dilutive on a GAAP basis due to acquisition-related charges

Transaction terms were not disclosed.

Bigger Picture

This deal reflects a broader shift in urology.

From behavioural therapy → implantable neuromodulation
From episodic care → automated, long-term solutions
From symptom management → durable quality-of-life improvement

For Boston Scientific, the Valencia acquisition is not just an add-on.
It’s a strategic move into the future of bladder care.